Clinical Trial Update: CD38-targeted Chimeric Antigen Receptor T Cell (CART) in Relapesd or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for CD38-targeted CAR-T therapy in relapsed or refractory acute myeloid leukemia (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CD38-targeted CAR-T therapy (CD38-targeted Chimeric Antigen Receptor T Cell)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: UNKNOWN